BridgeBio Pharma Inc.
BridgeBio Submits NDA for BBP-418 to Treat LGMD2I/R9
Summary
BridgeBio Pharma, Inc. has submitted a New Drug Application (NDA) to the FDA for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The submission is based on positive interim Phase 3 data showing significant improvements in ambulation and pulmonary function. If approved, BBP-418 could become the first therapy for LGMD2I/R9, with a U.S. launch anticipated in late 2026/early 2027.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement